Exposure to combination antiretroviral therapy (cART) can lead to important metabolic changes and increased risk of coronary heart disease (CHD). Computerized clinical decision support systems have been advocated to improve the management of patients at risk for CHD but it is unclear whether such systems reduce patients’ risk for CHD.
Methods
We conducted a cluster trial within the Swiss HIV Cohort Study (SHCS) of HIV-infected patients, aged 18 years or older, not pregnant and receiving cART for >3 months. We randomized 165 physicians to either guidelines for CHD risk factor management alone or guidelines plus CHD risk profiles. Risk profiles included the Framingham risk score, CHD drug prescriptions and CHD events based on biannual assessments, and were continuously updated by the SHCS data centre and integrated into patient charts by study nurses. Outcome measures were total cholesterol, systolic and diastolic blood pressure and Framingham risk score.
Results
A total of 3,266 patients (80% of those eligible) had a final assessment of the primary outcome at least 12 months after the start of the trial. Mean (95% confidence interval) patient differences where physicians received CHD risk profiles and guidelines, rather than guidelines alone, were total cholesterol -0.02 mmol/l (-0.09–0.06), systolic blood pressure -0.4 mmHg (-1.6– 0.8), diastolic blood pressure -0.4 mmHg (-1.5–0.7) and Framingham 10-year risk score -0.2% (-0.5–0.1).
Conclusions
Systemic computerized routine provision of CHD risk profiles in addition to guidelines does not significantly improve risk factors for CHD in patients on cART.
References
1.
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.Combination antiretroviral therapy and the risk of myocardial infarction.N Engl J Med2003; 349: 1993–2003.
2.
GrinspoonS., CarrA.Cardiovascular risk and body-fat abnormalities in HIV-infected adults.N Engl J Med2005; 352: 48–62.
3.
The DAD Study Group.Class of antiretroviral drugs and the risk of myocardial infarction.N Engl J Med2007; 356: 1723–1735.
4.
D:A:D Study Group.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.Lancet2008; 371: 1417–1426.
5.
KullerL.H., TracyR., BellosoW.Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.PLoS Med2008; 5: e203.
6.
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.CD4+ count-guided interruption of antiretroviral treatment.N Engl J Med2006; 355: 2283–2296.
7.
WolfK., TsakirisD.A., WeberR., ErbP., BattegayM.Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.J Infect Dis2002; 185: 456–462.
8.
GlassT.R., UngsedhapandC., WolbersM.Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study.HIV Med2006; 7: 404–410.
9.
FontasE., van LethF., SabinC.A.Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?J Infect Dis2004; 189: 1056–1074.
10.
Cholesterol Treatment Trialists’ (CTT) Collaborators.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet2005; 366: 1267–1278.
11.
Blood Pressure Lowering Treatment Trialists’ Collaboration.Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.Arch Intern Med2005; 165: 1410–1419.
12.
WuP., WilsonK., DimoulasP., MillsE.J.Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.BMC Public Health2006; 6: 300.
13.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive summary of the third report of the National Cholesterol Education Programme (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).JAMA2001; 285: 2486–2497.
14.
ChobanianA.V., BakrisG.L., BlackH.R.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.JAMA2003; 289: 2560–2572.
15.
DubeM.P., SteinJ.H., AbergJ.A.Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.Clin Infect Dis2003; 37: 613–627.
16.
LundgrenJ.D., BattegayM., BehrensG.European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.HIV Med2008; 9: 72–81.
17.
GlassT.R., WeberR., VernazzaP.L.Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study.HIV Clin Trials2007; 8: 77–85.
18.
SteinbergB.A., BhattD.L., MehtaS.Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease.Am Heart J2008; 156: 719–727.
19.
GargA.X., AdhikariN.K., McDonaldH.Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review.JAMA2005; 293: 1223–1238.
20.
EdwardsS.J., BraunholtzD.A., LilfordR.J., StevensA.J.Ethical issues in the design and conduct of cluster randomised controlled trials.BMJ1999; 318: 1407–1409.
21.
WilsonP.W., D'AgostinoR.B., LevyD., BelangerA.M., SilbershatzH., KannelW.B.Prediction of coronary heart disease using risk factor categories.Circulation1998; 97: 1837–1847.
22.
RiesenW.F., DarioliR., BertelO., BuserP.[Guidelines for the prevention of atherosclerosis].Schweiz Ärztezeitung2005; 86: 1355–1361. German.
23.
BucherH.C., WeberR., HirschelB.Management of risk factors of cardiovascular disease in HIV-infected patients receiving antiretroviral therapy. (Accessed 14 April 2009.) Available from http://www.ceb-institute.org/index.php?id=115&L=1.
24.
LowensteynI., JosephL., LevintonC., AbrahamowiczM., SteinertY., GroverS.Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS).Prev Med1998; 27: 730–737.
25.
Asymptomatic hypercholesterolemia: a clinical policy review.The Toronto Working Group on Cholesterol Policy.J Clin Epidemiol1990; 43: 1028–1121.
26.
DonnerA.Approaches to sample size estimation in the design of clinical trials – a review.Stat Med1984; 3: 199–214.
27.
HoganJ.W., RoyJ., KorkontzelouC.Handling drop-out in longitudinal studies.Stat Med2004; 23: 1455–1497.
28.
PocockS.J., AssmannS.E., EnosL.E., KastenL.E.Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems.Stat Med2002; 21: 2917–2930.
29.
KraemerH.C., BlaseyC.M.Centring in regression analyses: a strategy to prevent errors in statistical inference.Int J Methods Psychiatr Res2004; 13: 141–151.
30.
MontgomeryA.A., FaheyT., PetersT.J., MacIntoshC., SharpD.J.Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial.BMJ2000; 320: 686–690.
31.
BennerJ.S., ErhardtL., FlammerM.A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifable risk factor profile.Int J Clin Pract2008; 62: 1484–1498.
32.
WoodD.A., KotsevaK., ConnollyS.Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial.Lancet2008; 371: 1999–2012.
33.
RoumieC.L., ElasyT.A., GreevyR.Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial.Ann Intern Med2006; 145: 165–175.
34.
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.AIDS2008; 22: 2143–2153.
